Will M&A Pressure Mount After Pfizer-Allergan Merger?
This article was originally published in Scrip
Executive Summary
Large biotechnology companies are poised to become major players in mergers and acquisitions due to fast-growing cash stockpiles, but the pending $160bn merger of Pfizer Inc. and Allergan PLC may put pressure on other big pharma firms to make some major M&A moves.